Clinical Trials at The Methodist Hospital Research Institute |
Search results... |
Blood and Lymph Conditions |
| Active and enrolling clinical trials for Blood and Lymph Conditions are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health. |
| |
| For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250. |
| |
Embolism and Thrombosis
Ovation
Study Status: Active/Enrolling
Investigator: Lumsden, Alan
Study Coordinator: Josey, Jennifer
Phone: 713-441-4628
Summary:The primary objectives of this study are to determine whether the TriVascular AAA Stent Graft is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered...(read more)
VM202
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Bass, Anastasia
Phone: 713-441-6539
Summary:The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia(read more)
|
Hematologic Cancers
ENDEAVOR Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:This Phase 3 study is a multicenter, open-label, randomized trial in patients with multiple myeloma whose disease has relapsed after at least 1 but not more than 3 prior therapeutic regimens. Patients...(read more)
|
Lymphoma
C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Froehlich, Amber
Phone: 713-441-0685
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)
MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)
|
